CELZ

Business Context and Reporting Period

Company: Creative Medical Technology Holdings, Inc. (CELZ)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: A commercial-stage biotechnology company focused on immunotherapy, endocrinology, urology, neurology, and orthopedics. The company operates primarily through its subsidiary, Creative Medical Technologies, Inc. (CMT), marketing disposable kits for erectile and female sexual dysfunction. It is also developing stem cell-based therapies (ImmCelz, StemSpine, AlloCelz) for conditions including Type 1 Diabetes and chronic lower back pain.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Remained negligible. Nine-month revenue decreased from $8,000 in 2024 to $3,000 in 2025.
• Net Loss: Increased by 19% for the nine-month period (from $(3.64M) to $(4.11M)). The quarterly loss increased by 19% (from $(1.04M) to $(1.24M)).
• Operating Expenses:
  • Selling, General & Administrative (SG&A): Increased 30% year-over-year for the nine months ($2.40M vs $1.85M), driven by higher marketing expenses ($288k increase) and timing of bonus payouts ($191k increase).
  • Research & Development (R&D): Decreased 11% year-over-year for the nine months ($1.71M vs $1.93M), primarily due to reduced costs associated with the Type 1 Diabetes trial, partially offset by increased clinical research fees for the lower back pain trial.
• Other Income: Interest income decreased significantly (59% drop for nine months) due to lower short-term investment balances and interest rates.
• Capital Structure: The company raised approximately $3.7 million in net proceeds in March 2025 via a warrant exercise inducement transaction. Treasury stock increased by $10,000 due to share repurchases.

Outlook, Risks, and Unusual Items

• Clinical Progress:
  • CELZ-201 ADAPT (Lower Back Pain): Completed dosing of the second cohort (20 patients total) in Q2 2025. Initial data showed no serious adverse events and encouraging efficacy signals.
  • CELZ-201 CREATE-1 (Type 1 Diabetes): Received FDA Orphan Drug Designation in March 2024. Patient recruitment initiated in late 2023.
  • ImmCelz Platform: Validated via third-party studies showing reduced cell requirements and high purity.
• Subsequent Events (Post-Sept 30, 2025):
  • On October 25, 2025, the company closed another warrant exercise inducement transaction, raising approximately $3.8 million in net proceeds.
  • New warrants were issued with an exercise price re-priced to $2.86 based on VWAP.
• Liquidity: The company maintains positive working capital of approximately $5.15 million. Management states cash is sufficient for operations, though the company has a history of net losses and relies on financing activities (warrant exercises) to fund operations.
• Risks: Limited operating history, minimal revenue generation, dependence on successful clinical trials, and competition from well-funded entities. The company notes that adverse economic conditions or supply chain disruptions could materially affect operations.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $5.38M cash balance against the ~$4.1M net loss run rate for the nine-month period.
• Warrant Inducement Terms: Review the specific terms of the October 2025 warrant transaction (subsequent event) and the potential dilution impact of the new $2.86 exercise price warrants.
• Clinical Trial Milestones: Confirm the timeline and budget for the next phases of the CELZ-201 ADAPT and CREATE-1 trials, as these are the primary drivers for future valuation.
• Revenue Recognition: Investigate the source of the $3,000 revenue and the status of the $40,000 deferred revenue noted in prior periods to understand commercial traction.
• Related Party Transactions: Review ongoing obligations under the Lower Back Patent agreement with CMH and the ImmCelz license with Jadi Cell, LLC.